

What is claimed is:

1. An immunogenic composition comprising, in a physiologically acceptable vehicle, more than one
5 attenuated dengue virus chosen from the group consisting of dengue-1, dengue-2, dengue-3, dengue-4.

2. The immunogenic composition according to claim 1 which further comprises an adjuvant to enhance the
10 immune response.

3. The immunogenic composition of claim 1, formulated in a dose of 10^2 to 10^6 PFU of attenuated virus.
15

4. A method for stimulating dengue virus specific immune response, which comprises administering to an individual an immunologically sufficient amount of more than one attenuated virus chosen from the group
20 consisting of dengue-1, dengue-2, dengue-3, and dengue-4, in a physiologically acceptable carrier.

5. The method of claim 4, wherein the attenuated virus is administered parenterally.
25

6. The method of claim 4, wherein the attenuated virus is administered intranasally.

7. A multivalent live attenuated dengue virus
30 vaccine comprising any combination of dengue virus serotypes selected from the group consisting of: dengue 1, dengue 2, dengue 3, and dengue 4.

8. The vaccine of claim 7 wherein said dengue 1
35 is 45AZ5 PDK20 with ATCC No. VR-2648.

9. The vaccine of claim 7 wherein said dengue 2 is S16803 PDK50 with ATCC No. VR-2653.

5 10. The vaccine of claim 7 wherein said dengue 3 is CH5389 PDK20 with ATCC No. VR-2647.

11. The vaccine of claim 7 wherein said dengue 4 is 341750 PDK20 with ATCC No. VR-2652.

10

12. The vaccine of claim 7 wherein dengue 1 is 45AZ5 PDK20 with ATCC No. VR2648, dengue 2 is S16803 PDK50 with ATCC No. VR-2653, dengue 3 is CH5389 PDK20 with ATCC No. VR2647, and dengue 4 is 341750 PDK20
15 with ATCC No. VR-2652.

13. The dengue virus vaccine of claim 7 wherein said dengue virus is produced in vertebrate cells.

20 14. The dengue virus vaccine of claim 13 wherein said cells are Vero cells.

15. The dengue virus vaccine of claim 7 wherein said dengue-1 virus is in the amount of 10^2 to 10^7
25 pfu/ml, said dengue-2 virus is in the amount of 10^2 to 10^7 pfu, said dengue-3 virus is in the amount of 10^2 to 10^7 pfu, and said dengue-4 virus is in the amount of 10^2 to 10^7 pfu/ml.

30 16. The dengue virus vaccine of claim 15 wherein said vaccine is administered subcutaneously.